1. Yang W, Feng Y, Zhou J, Cheung OK, Cao JQ, Wang J, Tang WS, Tu YL, Xu LL, Wu F, Tan Z, Sun H, Tian Y, Wong J, Lai PB, Chan SL, Chan AW, Tan P, Chen Z, Sung JJ, Yip KYL, To KF, Cheng AS*. (2021) A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine, 13(588):eaaz6804.
2. Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F, Cheung OK, Sun H, Zeng X, Tang W, Mok MT, Wong J, Yeung PC, Lai PB, Jin H, Chen J, Chan SL, Chan AW, To KF, Chen Z, Sung JJ, Chen M, Cheng AS*. (2020). Targeting Monocyte-intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma. Gut, 69(2):365-379.
3. Yuan T, Yang B, Qiu W, Hao Y, Zhang Z, Yang B, Li N, Cheng S, Lin Z, Rui YC, Cheung OK, Wu WK, Yang W, Cheung Y, Lai PB, Luo J, Sung JJ, Chen R, Wang H, Cheng AS*, Yang P*. (2019). ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy. Nature Communications, 10(1):339 
4. Xiong L, Wu F, Wu Q, Xu L, Cheung OK, Kang W, Mok MT, Szeto LLM, Lun CY, Lung RW, Zhang J, Yu KH, Lee SD, Huang G, Wang CM, Liu J, Yu Z, Yu DY, Chou JL, Huang WH, Feng B, Cheung YS, Lai PB, Tan P, Wong N, Chan MW, Huang TH, Yip KY*, Cheng AS*, To KF*. (2019). Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. Nature Communications, 10(1):335.
5. Sun H, Yang W, Tian Y, Zeng X, Zhou J, Mok MTS, Tang W, Feng Y, Xu L, Chan AWH, Tong JH, Cheung YS, Lai PBS, Wang HKS, Tsang SW, Chow KL, Hu M, Liu R, Huang L, Yang B, Yang P, To KF, Sung JJY, Wong GLH*, Wong VWS*, Cheng AS*. (2018). An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nature Communications, 9(1):5214.
6. Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, Wang HK, Tsang SW, Goodwin T, Liu R, Huang L, Chen Z, Sung JJ, Chow KL, To KF, Cheng AS*. (2018). Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut, 67, 931-944.
7. Feng H, Yu Z, Tian Y, Lee YY, Li MS, Go MY, Cheung YS, Lai PB, Chan AM, To KF, Chan HL, Sung JJ, Cheng AS*. (2015). A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. Journal of Hepatology, 62(5), 1100-11
8. Yu Z, Gao YQ, Feng H, Lee YY, Li MS, Tian Y, Go MY, Yu DY, Cheung YS, Lai PB, Yu J, Wong VW, Sung JJ, Chan HL, Cheng AS*. (2014). Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. Gut, 63(11), 1793-1804. 
9. Cheng AS*, Li MS, Kang W, Cheng VY, Chou JL, Lau SS, Go MY, Lee CC, Ling TK, Ng EK, Yu J, Huang TH, To KF, Chan MW, Sung JJ, Chan FK*. (2013). Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. Gastroenterology, 144(1), 122-133.e9.
10. Feng H, Cheng AS*, Tsang DP, Li MS, Go MY, Cheung YS, Zhao GJ, Ng SS, Lin MC, Yu J, Lai PB, To KF, Sung JJ*. (2011). Cell cycle–related kinase is a direct androgen receptor-regulated gene driving ß-catenin/T-cell factor-dependent hepatocarcinogenesis. Journal of Clinical Investigation, 121(8), 3159-3175.

*(co-)corresponding author